SMS Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	8,971	7,827	7,093	5,221	5,199	5,632
Revenue	8,971	7,827	7,093	5,221	5,199	5,632
Revenue Growth (YoY)	14.96%	10.36%	35.86%	0.42%	-7.69%	35.93%
Cost of Revenue	6,058	5,241	4,983	3,900	3,309	3,797
Gross Profit	2,913	2,587	2,109	1,321	1,890	1,835
Selling, General & Admin	878.88	828.53	658.08	547.63	515.16	414.94
Other Operating Expenses	309.79	365.67	281.41	224.85	222.38	202.34
Operating Expenses	1,573	1,538	1,255	1,094	1,059	840.09
Operating Income	1,340	1,049	854.71	226.98	830.73	994.62
Interest Expense	-217.58	-174.35	-226.18	-209.94	-181.57	-102.54
Interest & Investment Income	6.87	6.87	7.58	7.75	5.6	3.14
Earnings From Equity Investments	24.74	17.37	6.26	-109.43	-56.61	15.62
Currency Exchange Gain (Loss)	50.78	50.78	28.98	39.05	25.8	5.71
Other Non Operating Income (Expenses)	0.61	-9.18	-4.39	-9.8	4.47	10.34
EBT Excluding Unusual Items	1,205	940.54	666.96	-55.4	628.42	926.9
Gain (Loss) on Sale of Assets	0.21	0.21	0.37	-0.54	-0.04	-0.08
Pretax Income	1,206	940.74	667.33	-55.94	628.38	926.82
Income Tax Expense	309.79	249.39	169.07	14.65	6.18	301.55
Earnings From Continuing Operations	895.9	691.35	498.26	-70.59	622.2	625.27
Minority Interest in Earnings	0.01	0.01	-	-	-	-
Net Income	895.91	691.36	498.26	-70.59	622.2	625.27
Net Income to Common	895.91	691.36	498.26	-70.59	622.2	625.27
Net Income Growth	35.54%	38.75%	-	-	-0.49%	98.04%
Shares Outstanding (Basic)	93	89	85	85	85	85
Shares Outstanding (Diluted)	93	89	85	85	85	85
Shares Change (YoY)	10.24%	4.72%	-	-	-	-
EPS (Basic)	9.61	7.80	5.89	-0.83	7.35	7.39
EPS (Diluted)	9.61	7.80	5.89	-0.83	7.35	7.39
EPS Growth	22.95%	32.49%	-	-	-0.49%	98.04%
Free Cash Flow	-	-416.71	-20.35	-74.71	178.12	-612.96
Free Cash Flow Per Share	-	-4.70	-0.24	-0.88	2.10	-7.24
Dividend Per Share	-	0.400	0.400	0.300	0.300	0.300
Dividend Growth	-	-	33.33%	-	-	20.00%
Gross Margin	32.47%	33.05%	29.74%	25.30%	36.35%	32.58%
Operating Margin	14.94%	13.40%	12.05%	4.35%	15.98%	17.66%
Profit Margin	9.99%	8.83%	7.03%	-1.35%	11.97%	11.10%
Free Cash Flow Margin	-	-5.32%	-0.29%	-1.43%	3.43%	-10.88%
EBITDA	1,700	1,387	1,163	541.39	1,142	1,207
EBITDA Margin	18.95%	17.72%	16.40%	10.37%	21.97%	21.43%
D&A For EBITDA	360.09	338.06	308.68	314.41	311.36	212.32
EBIT	1,340	1,049	854.71	226.98	830.73	994.62
EBIT Margin	14.94%	13.40%	12.05%	4.35%	15.98%	17.66%
Effective Tax Rate	25.69%	26.51%	25.34%	-	0.98%	32.54%
Revenue as Reported	9,043	7,890	7,137	5,270	5,251	5,666
Advertising Expenses	-	23.52	15.86	8.59	4	2.18

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.